Paradigm Biopharmaceuticals Ltd.ASX: PAR

Primary Endpoint Achieved in Phase 2 MPS VI Trial

Feb 9, 2024 at 3:25 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment